CA2932150A1 - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 - Google Patents

Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 Download PDF

Info

Publication number
CA2932150A1
CA2932150A1 CA2932150A CA2932150A CA2932150A1 CA 2932150 A1 CA2932150 A1 CA 2932150A1 CA 2932150 A CA2932150 A CA 2932150A CA 2932150 A CA2932150 A CA 2932150A CA 2932150 A1 CA2932150 A1 CA 2932150A1
Authority
CA
Canada
Prior art keywords
isolated peptide
pharmaceutical composition
seq
peptide
denoted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2932150A
Other languages
English (en)
French (fr)
Inventor
Raymond Kaempfer
Anat Shirvan
Gila Arad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATOX BIO Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
ATOX BIO Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATOX BIO Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical ATOX BIO Ltd
Publication of CA2932150A1 publication Critical patent/CA2932150A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
CA2932150A 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 Abandoned CA2932150A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361912631P 2013-12-06 2013-12-06
US61/912,631 2013-12-06
US201461924869P 2014-01-08 2014-01-08
US61/924,869 2014-01-08
PCT/IL2014/051067 WO2015083173A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Publications (1)

Publication Number Publication Date
CA2932150A1 true CA2932150A1 (en) 2015-06-11

Family

ID=52396781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932150A Abandoned CA2932150A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Country Status (7)

Country Link
US (2) US9963497B2 (https=)
EP (1) EP3077415B1 (https=)
JP (1) JP6757667B2 (https=)
AU (2) AU2014358677A1 (https=)
CA (1) CA2932150A1 (https=)
SG (2) SG10201804750XA (https=)
WO (1) WO2015083173A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077415B1 (en) * 2013-12-06 2020-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN111163792A (zh) 2017-10-06 2020-05-15 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于治疗病毒感染的肽
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN111253469B (zh) * 2020-03-06 2021-09-07 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
WO2023080790A1 (en) * 2021-11-02 2023-05-11 Tosoj As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
AU2003272065A1 (en) 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CA2860460A1 (en) 2012-01-16 2013-07-25 Atox Bio Ltd. Use of synthetic p2ta peptides in the treatment of ongoing bacterial infection and associated inflammation
EP3077415B1 (en) * 2013-12-06 2020-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Also Published As

Publication number Publication date
JP2017501999A (ja) 2017-01-19
US20180215804A1 (en) 2018-08-02
EP3077415B1 (en) 2020-02-12
WO2015083173A1 (en) 2015-06-11
JP6757667B2 (ja) 2020-09-23
AU2017261479A1 (en) 2017-11-30
US10280209B2 (en) 2019-05-07
AU2014358677A1 (en) 2016-06-02
AU2017261479B2 (en) 2019-05-02
US9963497B2 (en) 2018-05-08
SG10201804750XA (en) 2018-07-30
US20160289295A1 (en) 2016-10-06
EP3077415A1 (en) 2016-10-12
SG11201604512XA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US10280209B2 (en) Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
EP3281947B1 (en) Compositions and methods related to protein a (spa) variants
KR20220048988A (ko) 대식세포 특이적 인게이저 조성물 및 이의 사용 방법
EP2680872B1 (en) Use of pif peptides for treating infections, atherosclerosis and peritonitis
BR112013027547B1 (pt) polipeptídeo, dímero, composição, molécula de ácido nucleico, vetor de expressão recombinante, célula hospedeira microbiana, método para preparar o polipeptídeo e composição contendo nucleasse
KR20160020405A (ko) 약학적 조성물
RS67385B1 (sr) Antitela koja se vezuju za citrulinisani histon 2a i/ili 4
US20150376258A1 (en) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
ES2989890T3 (es) Proteínas de fusión de dominio extracelular de CD80-Fc para tratar tumores PD-L1 negativos
CN113508129A (zh) 突变的白介素-34(il-34)多肽及其在治疗中的用途
JP2023036860A (ja) 腫瘍浸潤ｔ細胞集団を生成する方法
KR102456666B1 (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
KR101913333B1 (ko) 신규 ctl 에피토프 4 연결 펩타이드
WO2020036987A1 (en) Peptides and compositions for targeted treatment and imaging
WO2016147182A1 (en) Isolated peptides derived from the b7 ligand dimer interface and uses thereof
CN106659764A (zh) 环状鞘脂激活蛋白原肽及其用途
EP3126377B1 (en) An isolated donor mhc-derived peptide and uses thereof
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
JP6758022B2 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
CA3218327A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
KR20180132766A (ko) 신규한 ｔｓｌｐ 저해인자
RU2851193C2 (ru) Мутантный полипептид интерлейкина-34 (IL-34) и его применение в терапии
HK40103919A (zh) 蛋白酶活化的多肽

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191120

FZDE Discontinued

Effective date: 20220607